Evidence map›Paper›PMID 31568492›Full record

ArticlePLoS pathogens2019

Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.

Nadine Bongard, Vu Thuy Khanh Le-Trilling, Anna Malyshkina, Meike Rückborn, Kerstin Wohlgemuth, Ina Wensing, Sonja Windmann, Ulf Dittmer, Mirko Trilling, Wibke Bayer

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nadine BongardInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Vu Thuy Khanh Le-TrillingInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-2733-3732
Anna MalyshkinaInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0001-5199-5472
Meike RückbornInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Kerstin WohlgemuthInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Ina WensingInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Sonja WindmannInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Ulf DittmerInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Mirko TrillingInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Wibke BayerInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-5885-5592

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunization vectors based on cytomegalovirus (CMV) have attracted a lot of interest in recent years because of their high efficacy in the simian immunodeficiency virus (SIV) macaque model, which has been attributed to their ability to induce strong, unusually broad, and unconventionally restricted CD8+ T cell responses. To evaluate the ability of CMV-based vectors to mediate protection by other immune mechanisms, we evaluated a mouse CMV (MCMV)-based vector encoding Friend virus (FV) envelope (Env), which lacks any known CD8+ T cell epitopes, for its protective efficacy in the FV mouse model. When we immunized highly FV-susceptible mice with the Env-encoding MCMV vector (MCMV.env), we could detect high frequencies of Env-specific CD4+ T cells after a single immunization. While the control of an early FV challenge infection was highly variable, an FV infection applied later after immunization was tightly controlled by almost all immunized mice. Protection of mice correlated with their ability to mount a robust anamnestic neutralizing antibody response upon FV infection, but Env-specific CD4+ T cells also produced appreciable levels of interferon γ. Depletion and transfer experiments underlined the important role of antibodies for control of FV infection but also showed that while no Env-specific CD8+ T cells were induced by the MCMV.env vaccine, the presence of CD8+ T cells at the time of FV challenge was required. The immunity induced by MCMV.env immunization was long-lasting, but was restricted to MCMV naïve animals. Taken together, our results demonstrate a novel mode of action of a CMV-based vaccine for anti-retrovirus immunization that confers strong protection from retrovirus challenge, which is conferred by CD4+ T cells and antibodies.

Indexed as

Adoptive TransferAnimalsAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleFriend murine leukemia virusGene Products, envGenetic VectorsImmunizationMiceMice, Inbred BALB CMice, Inbred C57BLMuromegalovirusRetroviridae InfectionsVaccines, SyntheticAntibodies, ViralGene Products, envVaccines, SyntheticViral Vaccines

Identifiers

PMID31568492
PMCPMC6786657
OpenAlexW2976107198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.